Urological Cancer Therapeutics Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
Urological Cancer Therapeutics Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Therapeutics Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Urological Cancer Therapeutics Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Urological Cancer Therapeutics Drugs worldwide, with company and product introduction, position in the Urological Cancer Therapeutics Drugs market
Market status and development trend of Urological Cancer Therapeutics Drugs by types and applications
Cost and profit status of Urological Cancer Therapeutics Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Urological Cancer Therapeutics Drugs market as:
Global Urological Cancer Therapeutics Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Urological Cancer Therapeutics Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Medical Research Laboratory
Others
Global Urological Cancer Therapeutics Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Urological Cancer Therapeutics Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Urological Cancer Therapeutics Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Therapeutics Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of Urological Cancer Therapeutics Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Urological Cancer Therapeutics Drugs worldwide, with company and product introduction, position in the Urological Cancer Therapeutics Drugs market
Market status and development trend of Urological Cancer Therapeutics Drugs by types and applications
Cost and profit status of Urological Cancer Therapeutics Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Urological Cancer Therapeutics Drugs market as:
Global Urological Cancer Therapeutics Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global Urological Cancer Therapeutics Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Global Urological Cancer Therapeutics Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Medical Research Laboratory
Others
Global Urological Cancer Therapeutics Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Urological Cancer Therapeutics Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER THERAPEUTICS DRUGS
1.1 Definition of Urological Cancer Therapeutics Drugs in This Report
1.2 Commercial Types of Urological Cancer Therapeutics Drugs
1.2.1 Xofigo (radium Ra 223 dichloride)
1.2.2 Jevtana (cabazitaxel)
1.2.3 Inlyta (axitinib)
1.2.4 Votrient (pazopanib hydrochloride)
1.2.5 Sutent (sunitinib malate)
1.2.6 Zytiga (abiraterone acetate)
1.2.7 Xtandi (enzalutamide)
1.2.8 Opdivo (nivolumab)
1.2.9 Provenge (sipuleucel-T)
1.3 Downstream Application of Urological Cancer Therapeutics Drugs
1.3.1 Hospital
1.3.2 Medical Research Laboratory
1.3.3 Others
1.4 Development History of Urological Cancer Therapeutics Drugs
1.5 Market Status and Trend of Urological Cancer Therapeutics Drugs 2013-2023
1.5.1 Global Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Urological Cancer Therapeutics Drugs 2013-2017
2.2 Production Market of Urological Cancer Therapeutics Drugs by Regions
2.2.1 Production Volume of Urological Cancer Therapeutics Drugs by Regions
2.2.2 Production Value of Urological Cancer Therapeutics Drugs by Regions
2.3 Demand Market of Urological Cancer Therapeutics Drugs by Regions
2.4 Production and Demand Status of Urological Cancer Therapeutics Drugs by Regions
2.4.1 Production and Demand Status of Urological Cancer Therapeutics Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Urological Cancer Therapeutics Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Urological Cancer Therapeutics Drugs by Types
3.2 Production Value of Urological Cancer Therapeutics Drugs by Types
3.3 Market Forecast of Urological Cancer Therapeutics Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry
4.2 Market Forecast of Urological Cancer Therapeutics Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Urological Cancer Therapeutics Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.2 Production Value of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.3 Basic Information of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Urological Cancer Therapeutics Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Urological Cancer Therapeutics Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 UROLOGICAL CANCER THERAPEUTICS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novartis
7.1.1 Company profile
7.1.2 Representative Urological Cancer Therapeutics Drugs Product
7.1.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Urological Cancer Therapeutics Drugs Product
7.2.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Johnson & Johnson
7.3.1 Company profile
7.3.2 Representative Urological Cancer Therapeutics Drugs Product
7.3.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.4 AstraZeneca
7.4.1 Company profile
7.4.2 Representative Urological Cancer Therapeutics Drugs Product
7.4.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.5 Astellas
7.5.1 Company profile
7.5.2 Representative Urological Cancer Therapeutics Drugs Product
7.5.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Astellas
7.6 Bristol-Myers Squibb
7.6.1 Company profile
7.6.2 Representative Urological Cancer Therapeutics Drugs Product
7.6.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.7 Abbott Laboratories
7.7.1 Company profile
7.7.2 Representative Urological Cancer Therapeutics Drugs Product
7.7.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.8 Celgene Corporation
7.8.1 Company profile
7.8.2 Representative Urological Cancer Therapeutics Drugs Product
7.8.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Dendreon Corporation
7.9.1 Company profile
7.9.2 Representative Urological Cancer Therapeutics Drugs Product
7.9.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.10 Ferring Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Urological Cancer Therapeutics Drugs Product
7.10.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.11 GlaxoSmithKline plc
7.11.1 Company profile
7.11.2 Representative Urological Cancer Therapeutics Drugs Product
7.11.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.12 Indevus Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Urological Cancer Therapeutics Drugs Product
7.12.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
7.13 Ipsen
7.13.1 Company profile
7.13.2 Representative Urological Cancer Therapeutics Drugs Product
7.13.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ipsen
7.14 Roche Healthcare
7.14.1 Company profile
7.14.2 Representative Urological Cancer Therapeutics Drugs Product
7.14.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
7.15 Sanofi S.A.
7.15.1 Company profile
7.15.2 Representative Urological Cancer Therapeutics Drugs Product
7.15.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
8.1 Industry Chain of Urological Cancer Therapeutics Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
9.1 Cost Structure Analysis of Urological Cancer Therapeutics Drugs
9.2 Raw Materials Cost Analysis of Urological Cancer Therapeutics Drugs
9.3 Labor Cost Analysis of Urological Cancer Therapeutics Drugs
9.4 Manufacturing Expenses Analysis of Urological Cancer Therapeutics Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Urological Cancer Therapeutics Drugs in This Report
1.2 Commercial Types of Urological Cancer Therapeutics Drugs
1.2.1 Xofigo (radium Ra 223 dichloride)
1.2.2 Jevtana (cabazitaxel)
1.2.3 Inlyta (axitinib)
1.2.4 Votrient (pazopanib hydrochloride)
1.2.5 Sutent (sunitinib malate)
1.2.6 Zytiga (abiraterone acetate)
1.2.7 Xtandi (enzalutamide)
1.2.8 Opdivo (nivolumab)
1.2.9 Provenge (sipuleucel-T)
1.3 Downstream Application of Urological Cancer Therapeutics Drugs
1.3.1 Hospital
1.3.2 Medical Research Laboratory
1.3.3 Others
1.4 Development History of Urological Cancer Therapeutics Drugs
1.5 Market Status and Trend of Urological Cancer Therapeutics Drugs 2013-2023
1.5.1 Global Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Urological Cancer Therapeutics Drugs 2013-2017
2.2 Production Market of Urological Cancer Therapeutics Drugs by Regions
2.2.1 Production Volume of Urological Cancer Therapeutics Drugs by Regions
2.2.2 Production Value of Urological Cancer Therapeutics Drugs by Regions
2.3 Demand Market of Urological Cancer Therapeutics Drugs by Regions
2.4 Production and Demand Status of Urological Cancer Therapeutics Drugs by Regions
2.4.1 Production and Demand Status of Urological Cancer Therapeutics Drugs by Regions 2013-2017
2.4.2 Import and Export Status of Urological Cancer Therapeutics Drugs by Regions 2013-2017
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Production Volume of Urological Cancer Therapeutics Drugs by Types
3.2 Production Value of Urological Cancer Therapeutics Drugs by Types
3.3 Market Forecast of Urological Cancer Therapeutics Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry
4.2 Market Forecast of Urological Cancer Therapeutics Drugs by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
5.1 Global Economy Situation and Trend Overview
5.2 Urological Cancer Therapeutics Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
6.1 Production Volume of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.2 Production Value of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.3 Basic Information of Urological Cancer Therapeutics Drugs by Major Manufacturers
6.3.1 Headquarters Location and Established Time of Urological Cancer Therapeutics Drugs Major Manufacturer
6.3.2 Employees and Revenue Level of Urological Cancer Therapeutics Drugs Major Manufacturer
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 UROLOGICAL CANCER THERAPEUTICS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novartis
7.1.1 Company profile
7.1.2 Representative Urological Cancer Therapeutics Drugs Product
7.1.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Urological Cancer Therapeutics Drugs Product
7.2.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Johnson & Johnson
7.3.1 Company profile
7.3.2 Representative Urological Cancer Therapeutics Drugs Product
7.3.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.4 AstraZeneca
7.4.1 Company profile
7.4.2 Representative Urological Cancer Therapeutics Drugs Product
7.4.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.5 Astellas
7.5.1 Company profile
7.5.2 Representative Urological Cancer Therapeutics Drugs Product
7.5.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Astellas
7.6 Bristol-Myers Squibb
7.6.1 Company profile
7.6.2 Representative Urological Cancer Therapeutics Drugs Product
7.6.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.7 Abbott Laboratories
7.7.1 Company profile
7.7.2 Representative Urological Cancer Therapeutics Drugs Product
7.7.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.8 Celgene Corporation
7.8.1 Company profile
7.8.2 Representative Urological Cancer Therapeutics Drugs Product
7.8.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Dendreon Corporation
7.9.1 Company profile
7.9.2 Representative Urological Cancer Therapeutics Drugs Product
7.9.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.10 Ferring Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Urological Cancer Therapeutics Drugs Product
7.10.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.11 GlaxoSmithKline plc
7.11.1 Company profile
7.11.2 Representative Urological Cancer Therapeutics Drugs Product
7.11.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.12 Indevus Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Urological Cancer Therapeutics Drugs Product
7.12.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
7.13 Ipsen
7.13.1 Company profile
7.13.2 Representative Urological Cancer Therapeutics Drugs Product
7.13.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ipsen
7.14 Roche Healthcare
7.14.1 Company profile
7.14.2 Representative Urological Cancer Therapeutics Drugs Product
7.14.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
7.15 Sanofi S.A.
7.15.1 Company profile
7.15.2 Representative Urological Cancer Therapeutics Drugs Product
7.15.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
8.1 Industry Chain of Urological Cancer Therapeutics Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
9.1 Cost Structure Analysis of Urological Cancer Therapeutics Drugs
9.2 Raw Materials Cost Analysis of Urological Cancer Therapeutics Drugs
9.3 Labor Cost Analysis of Urological Cancer Therapeutics Drugs
9.4 Manufacturing Expenses Analysis of Urological Cancer Therapeutics Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference